University of Wisconsin, Madison
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
The goal of this research study is to determine if DetectnetTM PET/CT scanning over several days can be used to deliver Lutathera in a safer manner. In this research, participants will be asked to complete a screening phase and possibly a dosimetry phase. The screening phase will require 2 visits. The dosimetry phase will also require 3 research visits.
Inclusion Criteria: * Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor Exclusion Criteria: * Unable to lie flat during or tolerate PET/CT or SPECT/CT * Known incompatibility to CT. SPECT, or PET scans * Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study
SPECT/CT will be performed after first cycle of Lutathera® treatment
PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
Standard of care administration of radioactive drug for PET/CT
Standard of care administration of radioactive drug for PET/CT and SPECT/CT
Arctuva estimate
Verify or correct the compensation shown for this listing.